Kineta Announces Participation in Upcoming October 2022 Investor Conferences
Seattle, WA – (October 10, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that ...
Kineta Appoints Keith Baker as Chief Financial Officer
Seattle, WA — (October 4, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the a ...
Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium
Seattle, WA — (September 14, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today tha ...
Kineta Announces Participation in the H.C. Wainwright 24th Annual Global Healthcare Conference
Seattle, WA — (September 12, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today th ...
Kineta Announces the Filing of a Registration Statement on Form S-4 with the U.S. SEC Related to the Reverse Merger with Yumanity Therapeutics (YMTX)
BOSTON, Aug. 29, 2022 -- Yumanity Therapeutics, Inc. ("Yumanity") (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying t ...
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer Seattle, WA — (June 28, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company foc ...
Kineta Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases
Kineta Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative DiseasesStrategic Alliance Combines ...
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit Seattle, WA — (June 17, 2022) Kineta, Inc. (“Kineta” or the “Compan ...
Kineta Announces Reverse Merger with NASDAQ-listed Yumanity Therapeutics (YMTX)
Yumanity Therapeutics announces definitive agreements for two strategic transactions Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered disco ...
Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022
Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022 Seattle, WA — (May 18, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of n ...